<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GLUCAGEN HYPOKIT- glucagon hydrochloride 
			 </strong><br>Novo Nordisk<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use GlucaGen safely and effectively. See full prescribing information for GlucaGen.<br>GlucaGen<span class="Sup">®</span> (glucagon [rDNA origin] for injection)<br>Initial U.S. Approval: 1998</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">GlucaGen is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated for: </p>
<dl>
<dt>•</dt>
<dd>Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (<a href="#i4i_indications_duplicate_id_3ef5e706-437c-4dbd-8bbf-cac18f432842">1.1</a>)</dd>
<dt>•</dt>
<dd>Use as a diagnostic aid (<a href="#i4i_indications_duplicate_id_96fc039d-8f6a-45e1-bf33-3eab1520c076">1.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (GlucaGen HypoKit)</span> </p>
<dl>
<dt>•</dt>
<dd>Reconstitute before administration. (<a href="#i4i_dosage_admin_duplicate_id_eb5fbc8c-a2de-4989-8830-8922abce1c40">2.1</a>)</dd>
<dt>•</dt>
<dd>Inject 1 mL (adults and children, weighing more than 55 lbs (25 kg)) or 0.5 mL (children weighing less than 55 lbs (25 kg)) subcutaneously, intramuscularly, or intravenously. (<a href="#i4i_dosage_admin_duplicate_id_eb5fbc8c-a2de-4989-8830-8922abce1c40">2.1</a>)</dd>
<dt>•</dt>
<dd>If the weight is not known: Children younger than 6 years should be given 0.5 mL and children 6 years and older should be given 1 mL. (<a href="#i4i_dosage_admin_duplicate_id_eb5fbc8c-a2de-4989-8830-8922abce1c40">2.1</a>)</dd>
<dt>•</dt>
<dd>Seek emergency assistance immediately after subcutaneous or intramuscular injection of glucagon. Glucagon injection may be repeated while waiting for emergency assistance. (<a href="#i4i_dosage_admin_duplicate_id_eb5fbc8c-a2de-4989-8830-8922abce1c40">2.1</a>)</dd>
<dt>•</dt>
<dd>Intravenous glucose MUST be administered if the patient fails to respond to glucagon. (<a href="#i4i_dosage_admin_duplicate_id_eb5fbc8c-a2de-4989-8830-8922abce1c40">2.1</a>)</dd>
<dt>•</dt>
<dd>When the patient responds to treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. (<a href="#i4i_dosage_admin_duplicate_id_eb5fbc8c-a2de-4989-8830-8922abce1c40">2.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">Use as a diagnostic aid (GlucaGen Diagnostic Kit and GlucaGen 10-Pack)</span> </p>
<dl>
<dt>•</dt>
<dd>Reconstitute before administration. (<a href="#i4i_dosage_admin_duplicate_id_39ef1443-9bd3-4c4f-a9a8-6692612aadad">2.2</a>)</dd>
<dt>•</dt>
<dd>The dose ranges from 0.2 mg to 2 mg depending on the diagnostic technique and the route of administration. (<a href="#i4i_dosage_admin_duplicate_id_39ef1443-9bd3-4c4f-a9a8-6692612aadad">2.2</a>)</dd>
<dt>•</dt>
<dd>After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied. (<a href="#i4i_dosage_admin_duplicate_id_39ef1443-9bd3-4c4f-a9a8-6692612aadad">2.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Each vial contains 1 mg/mL (1 unit/mL) GlucaGen when reconstituted with Sterile Water for Reconstitution or Sterile Water for Injection, USP. (<a href="#i4i_dosage_form_strength_id_b83723a3-4d27-46d5-a839-3444c3ced227">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to glucagon or lactose (<a href="#i4i_contraindications_id_586b9ccf-cfed-4dee-8b4e-9c92d724c95d">4</a>)</dd>
<dt>•</dt>
<dd>Do not use in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> (<a href="#i4i_contraindications_id_586b9ccf-cfed-4dee-8b4e-9c92d724c95d">4</a>)</dd>
<dt>•</dt>
<dd>Do not use in patients with <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span> (<a href="#i4i_contraindications_id_586b9ccf-cfed-4dee-8b4e-9c92d724c95d">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Administer cautiously to patients suspected of having <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span> or <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">glucagonoma</span> due to risk of secondary <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Glucagon may release catecholamines from <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> and is contraindicated in patients with this condition. (<a href="#i4i_section_id_27804fc4-e01e-49be-9743-e0a0eff01301">5.1</a>, <a href="#i4i_section_id_9538b1c7-f973-420f-8636-18a0615b3059">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may occur and include generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and in rare cases <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> with breathing difficulties, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#i4i_section_id_8f8457c4-50a3-4737-bda7-435339fa03ec">5.3</a>)</dd>
<dt>•</dt>
<dd>In order for GlucaGen treatment to reverse <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, there must be adequate amounts of glycogen stored in the liver. GlucaGen should be used with caution in patients with conditions resulting in low levels of releasable glucose in the liver. (<a href="#i4i_section_id_bda2095a-f764-431c-899e-396fe2f28282">5.4</a>) </dd>
<dt>•</dt>
<dd>Use caution when glucagon is used as a diagnostic aid in diabetic patients because it may cause <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. (<a href="#i4i_section_id_bda2095a-f764-431c-899e-396fe2f28282">5.4</a>)</dd>
<dt>•</dt>
<dd>Use with caution in patients with known cardiac disease, as glucagon increases myocardial oxygen demand. (<a href="#i4i_section_id_8f8a2fe7-b76f-499b-a11d-067e0de687b0">5.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions seen with GlucaGen are:  </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#i4i_adverse_effects_id_ab452059-002b-4045-a3a6-661cbb5d2b11">6</a>)</dd>
<dt>•</dt>
<dd>Temporary increase in blood pressure and pulse may occur after administration. (<a href="#i4i_adverse_effects_id_ab452059-002b-4045-a3a6-661cbb5d2b11">6</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-800-727-6500 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a><span class="Underline">.</span></span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Beta-blockers may cause a greater increase in both pulse and blood pressure after administration. (<a href="#i4i_interactions_id_7956efde-6ab1-4077-9740-3227e16e3a61">7.1</a>)</dd>
<dt>•</dt>
<dd>Glucagon may lose its ability to raise blood glucose or may produce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when given with indomethacin. (<a href="#i4i_interactions_id_7956efde-6ab1-4077-9740-3227e16e3a61">7.2</a>)</dd>
<dt>•</dt>
<dd>Coadministration with an anticholinergic drug is not recommended due to increased gastrointestinal side effects. (<a href="#i4i_section_id_8d5f725f-a8fd-430a-bd77-b75442e2aada">7.3</a>)</dd>
<dt>•</dt>
<dd>Glucagon may increase the anticoagulant effect of warfarin. (<a href="#i4i_interactions_id_7956efde-6ab1-4077-9740-3227e16e3a61">7.4</a>)</dd>
<dt>•</dt>
<dd>Insulin reacts antagonistically towards glucagon. (<a href="#i4i_section_id_262abb02-9604-42a4-9127-7a84b6e76f02">7.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing mothers: unknown whether drug is excreted in human milk, therefore caution should be exercised. (<a href="#i4i_nursing_mothers_id_03dadf91-7c98-4d0f-af15-4a5e63384658">8.3</a>)</dd>
<dt>•</dt>
<dd>Pediatrics: reported safe and effective for treatment of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Safety and effectiveness for use as a diagnostic aid have not been established. (<a href="#i4i_pediatric_use_id_44ff805f-f8dd-4eee-8de4-0b2a3abfb49d">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Use as a diagnostic aid</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Use as a diagnostic aid</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">Insulinoma</span> and <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">Glucagonoma</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Glycogen Stores and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Cardiac Disease</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Beta-blockers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Indomethacin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticholinergic Drugs</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Warfarin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Insulin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Recommended Storage</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">17.1 Physician Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_6f56c80b-f5b5-4fe4-ab06-d92ebddc7370"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_indications_duplicate_id_3ef5e706-437c-4dbd-8bbf-cac18f432842"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> </h2>
<p class="First">GlucaGen is used to treat severe hypoglycemic (low blood sugar) reactions which may occur in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus treated with insulin. Because GlucaGen depletes glycogen stores, the patient should be given supplemental carbohydrates as soon as he/she awakens and is able to swallow, especially children or adolescents. Medical evaluation is recommended for all patients who experience severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_indications_duplicate_id_96fc039d-8f6a-45e1-bf33-3eab1520c076"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Use as a diagnostic aid</h2>
<p class="First">GlucaGen is indicated for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract. Glucagon is as effective for this examination as are the anticholinergic drugs. However, the addition of the anticholinergic agent may result in increased side effects. After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_706520b0-fab2-4135-902e-c7e0b32da5a9"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For GlucaGen HypoKit:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_dosage_admin_duplicate_id_eb5fbc8c-a2de-4989-8830-8922abce1c40"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></h2>
<dl>
<dt>1.</dt>
<dd>Using the supplied prefilled syringe, carefully insert the needle through the rubber stopper of the vial containing GlucaGen powder and inject all the liquid from the syringe into the vial.</dd>
<dt>2.</dt>
<dd>Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted fluid should be clear and of water-like consistency.</dd>
<dt>3.</dt>
<dd>The reconstituted GlucaGen gives a concentration of approximately 1 mg/mL glucagon.</dd>
<dt>4.</dt>
<dd>The reconstituted GlucaGen should be used immediately after reconstitution.</dd>
<dt>5.</dt>
<dd>Inject 1 mL (adults and children, weighing more than 55 lbs (25 kg)) or 0.5 mL (children weighing less than 55 lbs (25 kg)) subcutaneously, intramuscularly, or intravenously. If the weight is not known: children younger than 6 years should be given a 0.5 mL and children 6 years and older should be given 1 mL. </dd>
<dt>6.</dt>
<dd><span class="Underline">Discard any unused portion.</span></dd>
<dt>7.</dt>
<dd>Emergency assistance should be sought immediately after subcutaneous or intramuscular injection of glucagon.</dd>
<dt>8.</dt>
<dd>The glucagon injection may be repeated using a new kit while waiting for emergency assistance.</dd>
<dt>9.</dt>
<dd>Intravenous glucose MUST be administered if the patient fails to respond to glucagon.</dd>
<dt>10.</dt>
<dd>When the patient has responded to the treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</dd>
<dt> </dt>
<dd><span class="Bold">For GlucaGen Diagnostic Kit and the GlucaGen 10-pack: </span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_dosage_admin_duplicate_id_39ef1443-9bd3-4c4f-a9a8-6692612aadad"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Use as a diagnostic aid</h2>
<p class="First">1. GlucaGen should be reconstituted with 1 mL of Sterile Water for Reconstitution (if supplied) or 1 mL of Sterile Water for Injection, USP. Using a syringe, withdraw all of the Sterile Water for Reconstitution (if supplied) or 1 mL Sterile Water for Injection, USP and inject into the GlucaGen vial.</p>
<p>2. Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted fluid should be clear and of water-like consistency.</p>
<p>3. The reconstituted GlucaGen gives a concentration of approximately 1 mg/mL glucagon. </p>
<p>4. The reconstituted GlucaGen should be used immediately after reconstitution.</p>
<p>5. GlucaGen must be administered by medical personnel.</p>
<p>6. <span class="Underline">Discard any unused portion.</span></p>
<p>7. Onset of action after an injection will depend on the organ under examination and route of administration [<span class="Italics"><a href="#i4i_pharmacodynamics_id_1e482371-f8b9-43d3-814a-c7416d1642d8">see Pharmacodynamics (12.2)</a></span>]. </p>
<p>8. The usual diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 mg to 0.5 mg given intravenously or 1 mg given intramuscularly; the usual dose to relax the colon is 0.5 mg to 0.75 mg intravenously and 1 mg to 2 mg intramuscularly [<span class="Italics"><a href="#i4i_pharmacodynamics_id_1e482371-f8b9-43d3-814a-c7416d1642d8">see Pharmacodynamics (12.2)</a></span>]. </p>
<p>9. After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied.</p>
<p><span class="Bold">The GlucaGen Diagnostic Kit and the GlucaGen 10-pack presentations are intended only for use by healthcare providers as a diagnostic aid. The GlucaGen Diagnostic Kit and the GlucaGen 10-pack presentations are not intended for use by patients to treat severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> because they are not packaged with a syringe and diluent necessary for rapid preparation and administration during an emergency outside of a healthcare facility.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_b83723a3-4d27-46d5-a839-3444c3ced227"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">GlucaGen is supplied in a vial, alone, or accompanied by Sterile Water for Reconstitution (1 mL) also in a vial (10 pack or diagnostic kit). It is also supplied as GlucaGen HypoKit<span class="Sup">®</span>, a presentation with a disposable prefilled syringe containing 1 mL Sterile Water for Reconstitution. When the glucagon powder is reconstituted with Sterile Water for Reconstitution (if supplied) or with Sterile Water for Injection, USP, it forms a solution of 1 mg/mL (1 unit/mL) glucagon for subcutaneous, intramuscular, or intravenous injection.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_586b9ccf-cfed-4dee-8b4e-9c92d724c95d"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">GlucaGen is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to glucagon, lactose or any other constituent in GlucaGen</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span> <span class="Italics"><a href="#i4i_section_id_27804fc4-e01e-49be-9743-e0a0eff01301">[see Warnings and Precautions (5.1)]</a></span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">Insulinoma</span> <span class="Italics"><a href="#i4i_section_id_9538b1c7-f973-420f-8636-18a0615b3059">[see Warnings and Precautions (5.2)]</a></span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_efa5427a-814d-43de-8c35-0d3d0faae3c1"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27804fc4-e01e-49be-9743-e0a0eff01301"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></h2>
<p class="First">Glucagon is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> because Glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9538b1c7-f973-420f-8636-18a0615b3059"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">Insulinoma</span> and <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">Glucagonoma</span></h2>
<p class="First">GlucaGen should be administered cautiously to patients suspected of having <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span> or <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">glucagonoma</span>. In patients with <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span>, intravenous administration of glucagon may produce an initial increase in blood glucose; however, glucagon administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span>. A patient developing symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> after a dose of glucagon should be given glucose orally or intravenously, whichever is most appropriate. Caution should also be observed in administering GlucaGen to patients with <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">glucagonoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f8457c4-50a3-4737-bda7-435339fa03ec"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may occur and include generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and in some cases <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> with breathing difficulties, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have generally occurred in association with endoscopic examination during which patients often received other agents including contrast media and local anesthetics. The patients should be given standard treatment for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> including an injection of epinephrine if they encounter respiratory difficulties after GlucaGen injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bda2095a-f764-431c-899e-396fe2f28282"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Glycogen Stores and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">In order for GlucaGen treatment to reverse <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, adequate amounts of glucose must be stored in the liver (as glycogen). Therefore, GlucaGen should be used with caution in patients with conditions such as prolonged fasting, <span class="product-label-link" type="condition" conceptid="443082" conceptname="Starvation">starvation</span>, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or chronic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> because these conditions result in low levels of releasable glucose in the liver and an inadequate reversal of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> by GlucaGen treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f8a2fe7-b76f-499b-a11d-067e0de687b0"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Cardiac Disease</h2>
<p class="First">Caution should be observed when glucagon is used as an adjunct in endoscopic or radiographic procedures to inhibit gastrointestinal motility in patients with known cardiac disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35c5dba9-eee9-4964-b6ee-7db96a71fdb9"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Laboratory Tests</h2>
<p class="First">Blood glucose measurements may be considered to monitor the patient’s response.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ab452059-002b-4045-a3a6-661cbb5d2b11"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Side effects may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> at doses above 1 mg or with rapid injection. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has been reported up to 2 hours after administration in patients receiving GlucaGen as premedication for upper GI endoscopy procedures. Glucagon exerts positive inotropic and chronotropic effects and may, therefore, cause <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Adverse reactions indicating toxicity of GlucaGen have not been reported. A temporary increase in both blood pressure and pulse rate may occur following the administration of glucagon. Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of glucagon’s short half-life <span class="Italics"><a href="#i4i_section_id_60d52cea-5712-4b36-8d9e-3e91e04c9724">[see Drug Interactions (7.1)]</a></span>. The increase in blood pressure and pulse rate may require therapy in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> <span class="Italics"><a href="#i4i_section_id_27804fc4-e01e-49be-9743-e0a0eff01301">[see Warnings and Precautions (5.1)]</a>.</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> may occur in some cases <span class="Italics"><a href="#i4i_section_id_8f8457c4-50a3-4737-bda7-435339fa03ec">[see Warnings and Precautions (5.3)]</a></span>.</p>
<p>The following adverse reactions have been identified during postapproval use of GlucaGen. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency.</p>
<a name="_Refid_719831e9-8cbd-4ddd-95ce-ea5bc6623"></a><table width="100%">
<caption><span>Table 1 Frequency of Adverse Reactions</span></caption>
<col width="53%">
<col width="47%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" colspan="2"><p class="First"><span class="Bold">Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></span></p></td></tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Frequency (%)</span></p></td>
<td class="Botrule"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 10</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
</tr>
<tr><td class="Botrule" colspan="2"><p class="First"><span class="Bold">Use as a diagnostic aid</span></p></td></tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 10</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">&lt;1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">Hypoglycemic coma</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_7956efde-6ab1-4077-9740-3227e16e3a61"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60d52cea-5712-4b36-8d9e-3e91e04c9724"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Beta-blockers</h2>
<p class="First">Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of glucagon’s short half-life. The increase in blood pressure and pulse rate may require therapy in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c85d650e-d032-44a0-9be7-37ad9a13afb0"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Indomethacin</h2>
<p class="First">When used with indomethacin, glucagon may lose its ability to raise blood glucose or may even produce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Therefore, caution should be exercised for patients taking indomethacin when glucagon will be administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d5f725f-a8fd-430a-bd77-b75442e2aada"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticholinergic Drugs</h2>
<p class="First">Coadministration with an anticholinergic drug is not recommended due to increased gastrointestinal side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_333042d3-993a-4cb6-aa20-c638a5f2efcd"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Warfarin</h2>
<p class="First">Glucagon may increase the anticoagulant effect of warfarin. Therefore, caution should be exercised for patients taking warfarin when glucagon will be administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_262abb02-9604-42a4-9127-7a84b6e76f02"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Insulin</h2>
<p class="First">Insulin reacts antagonistically towards glucagon. Therefore, caution should be exercised when glucagon is used as a diagnostic aid in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_dba5c9eb-9106-46c2-bd43-ea84ca230f70"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8a475021-2b75-4aae-9826-5e79e5e29612"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. Reproduction studies were performed in rats and rabbits at GlucaGen doses of 0.4, 2.0, and 10 mg/kg. These doses represent exposures of up to 100 and 200 times the human dose based on mg/m<span class="Sup">2</span> for rats and rabbits, respectively, and revealed no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Glucagon does not cross the human placenta barrier.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_03dadf91-7c98-4d0f-af15-4a5e63384658"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GlucaGen is administered to a nursing woman. No clinical studies have been performed in nursing mothers, however, GlucaGen is a peptide and intact glucagon is not absorbed from the GI tract. Therefore, even if the infant ingested glucagon it would be unlikely to have any effect on the infant. Additionally, GlucaGen has a short plasma half-life thus limiting amounts available to the child. Glucagon does not cross the human placental barrier.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_44ff805f-f8dd-4eee-8de4-0b2a3abfb49d"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">For the treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>: The use of glucagon in pediatric patients has been reported to be safe and effective.</p>
<p>For use as a diagnostic aid: Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_fe9b0ec3-6c3a-4360-92b7-cef04f70e3e1"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No reports of overdosage with GlucaGen have been reported. If overdosage occurs, the patient may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, inhibition of GI tract motility, increase in blood pressure and pulse rate.  In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_2efe4975-862a-4864-aaa7-e7dc14b3522f"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">GlucaGen (glucagon [rDNA origin] for injection) is an antihypoglycemic agent and a gastrointestinal motility inhibitor. It is produced by expression of recombinant DNA in a <span class="Italics">Saccharomyces cerevisiae</span> vector with subsequent purification. The chemical structure of the glucagon in GlucaGen is identical to human glucagon and to glucagon extracted from beef and pork pancreas. Glucagon with the empirical formula of C<span class="Sub">153</span>H<span class="Sub">225</span>N<span class="Sub">43</span>O<span class="Sub">49</span>S, and a molecular weight of 3483, is a single-chain polypeptide containing 29 amino acid residues. The structure of glucagon is:</p>
<div class="Figure">
<a name="id702"></a><img alt="Structural formula of GlucaGen." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-01.jpg">
</div>
<p>GlucaGen is a sterile, lyophilized white powder in a 2 mL vial. The reconstituted solution contains glucagon as hydrochloride 1 mg/mL (1 unit/mL) and lactose monohydrate (107 mg). GlucaGen is supplied at pH 2.5-3.5 and is soluble in water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e6fb77ec-b1ef-4828-a41d-608ea5e29357"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_5e1a9f20-2fe1-47d8-9efc-1fdbecb42fb5"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Bold">Antihypoglycemic Action:</span> Glucagon induces liver glycogen breakdown, releasing glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.</p>
<p><span class="Bold">Gastrointestinal Motility Inhibition:</span> Extra hepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_1e482371-f8b9-43d3-814a-c7416d1642d8"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold">For the treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>:</span></p>
<p>Blood glucose concentration rises within 10 minutes of injection and maximal concentrations are attained at approximately 30 minutes after injection (see Figure 1). The duration of hyperglycemic action after intravenous or intramuscular injection is 60 – 90 minutes.</p>
<div class="Figure">
<a name="id734"></a><img alt="Graph " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-02.jpg">
</div>
<p><span class="Bold">Figure 1. Recovery from Insulin Induced <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> (mean blood glucose) After Intramuscular Injection of 1 mg GlucaGen in Type I Diabetic Men</span></p>
<p><span class="Bold">For use as a diagnostic aid:</span></p>
<a name="_Refid_67ef0daa-c905-42a7-8769-fac7980a5"></a><table width="100%">
<caption><span>Table 2 Pharmacodynamic Properties of Glucagon</span></caption>
<col width="16%">
<col width="21%">
<col width="21%">
<col width="21%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The usual diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 – 0.5 mg given intravenously or 1 mg given intramuscularly; the usual dose to relax the colon is 0.5 – 0.75 mg intravenously and 1 – 2 mg intramuscularly.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Note: The time of maximal glucose concentration for GlucaGen administered subcutaneously is 30-45 minutes.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Route of Administration</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Dose</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Time of Maximal Glucose Concentration</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Time of Onset of Action for GI Smooth <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">Muscle Relaxation</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Duration of Smooth <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">Muscle Relaxation</span></span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2"><p class="First"><span class="Bold">IV</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">0.25-0.5 mg (0.25-0.5 units)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">5-20 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">45 seconds</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">9-17 minutes</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">2 mg (2 units)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">5-20 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">45 seconds</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">22-25 minutes</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2"><p class="First"><span class="Bold">IM</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">1 mg (1 unit)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">30 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">8-10 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">12-27 minutes</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">2 mg (2 units)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">30 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">4-7 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">21-32 minutes</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_53cff6df-b389-4c31-be9b-21910afab2c1"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Intramuscular injection of 1 mg GlucaGen resulted in a mean C<span class="Sub">max</span> (CV%) of 1686 pg/mL (43%) and median T<span class="Sub">max</span> of 12.5 minutes. The mean apparent half-life of 45 minutes after intramuscular injection probably reflects prolonged absorption from the injection site. Glucagon is degraded in the liver, kidney, and plasma. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_6b159bff-84b9-4c18-b6ab-574249fb741e"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ecfcaa63-2628-4437-8176-dd40ca8651a9"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals to evaluate carcinogenic potential have not been performed. Several studies have been conducted to evaluate the mutagenic potential of glucagon. The mutagenic potential tested in the Ames and human lymphocyte assays, was borderline positive under certain conditions for both glucagon (pancreatic) and glucagon (rDNA) origin. <span class="Italics">In vivo</span>, very high doses (100 and 200 mg/kg) of glucagon (both origins) gave a slightly higher incidence of micronucleus formation in male mice but there was no effect in females. The weight of evidence indicates that GlucaGen is not different from glucagon pancreatic origin and does not pose a genotoxic risk to humans. GlucaGen (rDNA origin) was not tested in animal fertility studies. Studies in rats have shown that pancreatic glucagon does not cause impaired fertility. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_b52f0450-b95c-4582-8387-313bcf6fede1"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9894b049-c2bd-4059-b642-5f61b5168f65"></a><a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">GlucaGen is supplied as a sterile, lyophilized white powder in a vial, alone, or accompanied by Sterile Water for Reconstitution also in a vial (Diagnostic Kit or 10-pack). It is also supplied as GlucaGen HypoKit with a disposable prefilled syringe containing Sterile Water for Reconstitution.</p>
<p><span class="Bold">GlucaGen HypoKit includes:  <span class="Italics"><br></span></span>1 vial containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)<br>1 disposable syringe containing 1 mL Sterile Water for Reconstitution<br>NDC 0169-7065-15</p>
<p><span class="Bold">GlucaGen Diagnostic Kit (NDC 0597-0260-10) includes:<br></span>1 vial containing 1 mg (1 unit) GlucaGen<span class="Sup"></span>(glucagon [rDNA origin] for injection)<br>NDC 0597-0053-01<br>1 vial containing 1 mL Sterile Water for Reconstitution<br>NDC 0597-0265-94</p>
<p><span class="Bold">GlucaGen Diagnostic Kit is also available as (NDC 55390-004-01) and includes:<br></span>1 vial containing 1 mg (1 unit) GlucaGen<span class="Sup"></span>(glucagon [rDNA origin] for injection)<br>NDC 55390-004-01<br>1 vial containing 1 mL Sterile Water for Reconstitution</p>
<p><span class="Bold">GlucaGen HypoKit (Two-Pack) includes: </span>2 packs of GlucaGen HypoKit, <br>Each HypoKit contains: <br>1 vial containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection) <br>1 disposable syringe containing 1 mL Sterile Water for Reconstitution<br>NDC 0169-7065-21</p>
<p><span class="Bold">The GlucaGen 10-pack includes:<br></span>10 vials, each containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)<br>NDC 55390-004-10<br>NDC 0597-0053-45</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7396360b-72ab-4372-b590-63f89533c88a"></a><a name="section-13.2"></a><p></p>
<h2>16.2 Recommended Storage</h2>
<p class="First"><span class="Bold">Before Reconstitution:</span></p>
<p>The GlucaGen package may be stored up to 24 months at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span> C (68<span class="Sup">o</span> to 77<span class="Sup">o </span>F) prior to reconstitution. Do not freeze. Keep in the original package to protect from light. GlucaGen should not be used after the expiry date on the vials.</p>
<p><span class="Bold">After Reconstitution:</span></p>
<p>Reconstituted GlucaGen should be used immediately. <span class="Underline">Discard any unused portion</span>. If the solution shows any sign of gel formation or particles, it should be discarded. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_d02c0983-0312-41d0-95f2-88b7c1a91179"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">[S<span class="Italics">ee FDA-Approved Patient Labeling (Patient Instructions for Emergency Use).</span>]</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a649adf-fff4-4b7d-a629-3ea72c36ae90"></a><a name="section-14.1"></a><p></p>
<h2>17.1 Physician Instructions</h2>
<p class="First">Refer patients and family members to the FDA-approved patient labeling for instructions describing the method of preparing and injecting GlucaGen. Advise the patient and family members to become familiar with the technique of preparing glucagon before an emergency arises. Instruct patients to use 1 mg for adults or ½ the adult dose (0.5 mg) for children weighing less than 55 lb (25 kg). To prevent severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, patients and family members should be informed of the symptoms of mild <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and how to treat it appropriately. Family members should be informed to arouse the patient as quickly as possible because prolonged <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may result in damage to the central nervous system. Patients should be advised to inform their physician when <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reactions</span> occur so that the treatment regimen may be adjusted if necessary.</p>
<p>No studies on the effects on the ability to drive and use machines have been performed. After diagnostic procedures, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> has been reported infrequently. The patient’s ability to concentrate and react may be impaired as a result of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This may present a risk in situations where these abilities are especially important, such as driving or operating machinery. Therefore, these activities should be avoided until the patient has had a meal with oral carbohydrates.</p>
<p>Date of issue: December 12, 2014</p>
<p>Version: 6</p>
<p><span class="Italics">GlucaGen<span class="Sup">®</span> and HypoKit<span class="Sup">® </span>are registered trademarks of Novo Nordisk A/S </span></p>
<p><span class="Italics">© 1998-2014 Novo Nordisk</span></p>
<p>For information contact:<br>Novo Nordisk Inc.<br>800 Scudders Mill Road<br>Plainsboro, NJ 08536, USA<br>1-800-727-6500<br>www.novonordisk-us.com</p>
<p>Manufactured by:<br>Novo Nordisk A/S<br>2880 Bagsvaerd, Denmark</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_4a052688-33ab-4a10-a92e-d59b05762d25"></a><a name="section-15"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"><span class="Bold">INSTRUCTIONS FOR EMERGENCY USE</span></p>
<p><span class="Bold">GlucaGen<span class="Sup">®</span> (Glū-ka-Gen)</span><br><span class="Bold">(glucagon [rDNA origin] for injection)</span><br><span class="Bold">HypoKit<span class="Sup">®</span></span></p>
<p><span class="Bold">1. GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span> is for use in case of emergency for very low blood sugar (severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) in people with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who use insulin.</span></p>
<p><span class="Bold">2. Read and become familiar with the following instructions before an emergency happens. If you have questions about using GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span> talk with your doctor or pharmacist.</span></p>
<p> <span class="Bold">What is the most important information I should know about GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span>?</span></p>
<dl>
<dt> </dt>
<dd>1.<span class="Bold"> Make sure that your family members, coworkers, or close friends know that if you become <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> they should use this kit right away.</span> They should call for emergency medical help immediately after using the kit.</dd>
<dt> </dt>
<dd>2. <span class="Bold">Show your family members and others where you keep this kit and how to use it. </span>They need to know how to use it before you need it. They can practice giving a shot by giving you your normal insulin shots. It is important that they practice. A person who has never given a shot may not be able to give one in an emergency.</dd>
<dt> </dt>
<dd>3. <span class="Bold">It is important that your family member or friend:</span>
</dd>
</dl>
<dl>
<dt>•</dt>
<dd>Act quickly. Being <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> for a period of time may be harmful. Follow these instructions to give GlucaGen<span class="Sup">®</span> the right way.</dd>
<dt>•</dt>
<dd>Turn the <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> person on their side to prevent <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span>.</dd>
<dt>•</dt>
<dd>Do not mix GlucaGen<span class="Sup">®</span> until they are ready to use it.</dd>
<dt>•</dt>
<dd>Mix the GlucaGen<span class="Sup">®</span>. The syringe does not have GlucaGen<span class="Sup">®</span> in it. You must mix the contents of the syringe with GlucaGen<span class="Sup">®</span> in the vial provided in GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span> before giving the injection. (See Instructions for Use)</dd>
<dt>•</dt>
<dd>Throw away any mixed GlucaGen<span class="Sup">®</span> that is not used.</dd>
</dl>
<p>The patient may be in a <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> from very high blood sugar (severe <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>), rather than very low blood sugar. If this is the case, the <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> person will not respond to GlucaGen<span class="Sup">®</span>. </p>
<p><span class="Bold">What is GlucaGen<span class="Sup">®</span>?</span></p>
<p>GlucaGen<span class="Sup">®</span> is a prescription medicine used to treat very low blood sugar that can happen in people who have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and use insulin. </p>
<p><span class="Bold">Symptoms of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> include: </span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. </p>
<p><span class="Bold">You should only give GlucaGen<span class="Sup">®</span> injection if: </span></p>
<dl>
<dt> </dt>
<dd>1. the person is <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> or</dd>
<dt> </dt>
<dd>2. the person is having a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or</dd>
<dt> </dt>
<dd>3. the person is <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> and unable to eat sugar or a sugar-sweetened product.</dd>
</dl>
<p>GlucaGen<span class="Sup">®</span> may have been prescribed so that your friends or family members can give the injection if you become hypoglycemic and are unable to take sugar by mouth. </p>
<p>Less severe cases of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> should be treated right away by eating sugar or a sugar-sweetened product such as a regular soft drink or fruit juice.</p>
<p>GlucaGen<span class="Sup">®</span> does not work if it is taken by mouth.</p>
<p><span class="Bold">Who should not use GlucaGen<span class="Sup">®</span>?</span></p>
<p>Do not use GlucaGen<span class="Sup">® </span>if the person: </p>
<dl>
<dt>•</dt>
<dd>is allergic to either glucagon or lactose </dd>
<dt>•</dt>
<dd>has a tumor of the adrenal gland called a <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span></dd>
<dt>•</dt>
<dd>has a tumor of the pancreas called <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span></dd>
</dl>
<p><span class="Bold">Instructions for Use:</span></p>
<p><span class="Bold">To Prepare GlucaGen<span class="Sup">®</span> For Injection:</span></p>
<p>GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span> includes: </p>
<dl>
<dt>•</dt>
<dd>1 vial containing 1 mg GlucaGen<span class="Sup">®</span> powder (glucagon [rDNA origin] for injection)</dd>
<dt>•</dt>
<dd>1 prefilled disposable syringe with attached needle containing 1 mL solvent (sterile water) for reconstitution </dd>
</dl>
<div class="Figure">
<a name="id1007"></a><img alt="Content of GlucaGen Hypokit" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-03.jpg">
</div>
<p>The vial with GlucaGen<span class="Sup">®</span> in it has a protective plastic cap. You must remove the plastic cap to inject the water and mix the GlucaGen<span class="Sup">®</span>. If the cap is loose or missing when you buy the package, return it to your local pharmacy. </p>
<p>Use the prefilled disposable syringe that comes in GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span>, with the attached needle, to mix the GlucaGen<span class="Sup">®</span> and sterile water before giving the injection.</p>
<p><span class="Bold">Step 1.</span> Take the orange plastic cap off the vial of GlucaGen<span class="Sup">®</span>. See Figure A.</p>
<div class="Figure">
<a name="id1018"></a><img alt="Step 1: Take the orange plastic cap off the vial." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-04.jpg"><p class="MultiMediaCaption">Figure A </p>
</div>
<p>Figure A </p>
<p><span class="Bold">Step 2.</span> Pull the needle cover off the needle. See Figure B.</p>
<div class="Figure">
<a name="id1022"></a><img alt="Step 2: Pull the needle cover off." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-05.jpg"><p class="MultiMediaCaption">Figure B </p>
</div>
<p>Figure B </p>
<p><span class="Bold">Step 3.</span> Insert the needle through the rubber stopper (within the marked circle) of the vial containing GlucaGen<span class="Sup">®</span> and inject all the liquid from the syringe into the vial. See Figure C.</p>
<div class="Figure">
<a name="id1027"></a><img alt="Step 3: Insert needle through rubber stopper." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-06.jpg"><p class="MultiMediaCaption">Figure C </p>
</div>
<p>Figure C </p>
<p><span class="Bold">Step 4</span>. Without taking the syringe and needle out of the vial, gently shake the vial in your hand until the powder dissolves completely. See Figure D. The liquid should be clear. Do not use if the liquid has any particles in it or it is not clear.</p>
<div class="Figure">
<a name="id1031"></a><img alt="Step 4: Gently shake the vial." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-07.jpg"><p class="MultiMediaCaption">Figure D </p>
</div>
<p>Figure D </p>
<p><span class="Bold">Step 5</span>. Without taking the syringe and needle out of the vial, turn the vial upside down. Keep the needle in the liquid. Gently pull back on the plunger and slowly withdraw all the liquid into the syringe. See Figure E. Do not pull the plunger out of the syringe. This helps prevent the medicine from leaking out of the syringe.</p>
<div class="Figure">
<a name="id1035"></a><img alt="Step 5: Pull back plunger and slowly withdraw liquid into syringe." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-08.jpg"><p class="MultiMediaCaption">Figure E </p>
</div>
<p>Figure E </p>
<dl>
<dt>•</dt>
<dd>The usual dose for adults and children who weigh more than 55 pounds (25 kg) is 1 mg (1 mL). Withdraw the liquid to 1 mL mark on the syringe. See Figure F.</dd>
<dt>•</dt>
<dd>The usual dose for children who weigh less than 55 pounds (25 kg) is 0.5 mg (half of the adult dose). Withdraw the liquid to the 0.5 mL mark on the syringe for these children. See Figure F.</dd>
</dl>
<div class="Figure">
<a name="id1041"></a><img alt="Figure F: Dosage for children and adults." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-09.jpg"><p class="MultiMediaCaption">Figure F </p>
</div>
<p>Figure F </p>
<p><span class="Bold">If you do not know how much the child weighs:</span></p>
<dl>
<dt>•</dt>
<dd>Give a child under 6 years of age 0.5 mg (0.5 mL).</dd>
<dt>•</dt>
<dd>Give a child 6 years of age and older 1 mg (1 mL).</dd>
</dl>
<p><span class="Bold">Step 6</span>. Keep the needle in the liquid inside the vial. Remove any air bubbles in the syringe by flicking the syringe with your finger. See Figure G. Gently push on the plunger to move any air bubbles out of the syringe and into the vial.</p>
<div class="Figure">
<a name="id1050"></a><img alt="Step 6: Keep the needle in the liquid inside the vial." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-10.jpg"><p class="MultiMediaCaption">Figure G </p>
</div>
<p>Figure G </p>
<p> Continue pushing the plunger until you have the correct dose as described in Step 5. If the plunger is pushed below the needed dose, pull back the plunger until you have the correct dose. When you have a correct amount of GlucaGen<span class="Sup">®</span> in the syringe, take the syringe with the attached needle out of the vial.</p>
<p><span class="Bold">To Inject GlucaGen<span class="Sup">®</span>:</span></p>
<p><span class="Bold">Step 7.</span> See Figure H for commonly used injection sites. Choose an area for injection.</p>
<p><span class="Bold">Common injection sites</span></p>
<div class="Figure">
<a name="id1061"></a><img alt="Step 7: Commonly used injection sites." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-11.jpg"><p class="MultiMediaCaption">Figure H </p>
</div>
<p>Figure H </p>
<p>Insert the needle into the loose tissue at the injection site, and inject the GlucaGen<span class="Sup">®</span>. See Figure I.</p>
<div class="Figure">
<a name="id1065"></a><img alt="Insert the needle into the loose tissue at the injection site and inject GlucaGen ." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-12.jpg"><p class="MultiMediaCaption">Figure I </p>
</div>
<p>Figure I </p>
<p><span class="Bold">After Giving the GlucaGen<span class="Sup">®</span></span><span class="Sup"> </span><span class="Bold">Injection:</span></p>
<p><span class="Bold">Step 8. </span>Withdraw the needle and press on the injection site. See Figure J<span class="Bold">.</span></p>
<div class="Figure">
<a name="id1074"></a><img alt="Step 8: Withdraw the needle and press the injection site." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-13.jpg"><p class="MultiMediaCaption">Figure J </p>
</div>
<p>Figure J </p>
<p>Place the used syringe with attached needle in a sharps container (such as a red biohazard container), a hard plastic container (such as a detergent bottle), or a metal container (such as an empty coffee can). Seal the container and throw it away the right way. There may be state and local laws about the right way to throw away used syringes and needles. Ask your doctor or pharmacist how to throw away used syringes and needles. Throw away any GlucaGen<span class="Sup">® </span>you do not use.</p>
<p><span class="Bold">Step 9. Turn the person on their side.</span> When an <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> person awakens, they may vomit. Turning the person on their side will lessen the chance of <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span>.</p>
<p><span class="Bold">Step 10. Call for emergency medical help right away.</span></p>
<p><span class="Bold">Step 11</span>. <span class="Bold">Feed the person as soon as they are awake and able to swallow</span>. Give the person a fast-acting source of sugar (such as a regular soft drink or fruit juice) and a long-acting source of sugar (such as crackers and cheese or a meat sandwich). If the person does not awaken within 15 minutes, give another dose of GlucaGen<span class="Sup">®</span> using a new kit. </p>
<p><span class="Bold">Step 12</span>. <span class="Bold">Even if the GlucaGen<span class="Sup">®</span> treatment awakens the person, tell their doctor right away.</span> The doctor should be told whenever a severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> reaction happens. The person’s dose of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine may need to be changed.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may happen again after receiving GlucaGen<span class="Sup">®</span> treatment.</span></p>
<p><span class="Bold">Early symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may include:</span></p>
<table width="100%">
<col width="51%">
<col width="49%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span></dd>
<dt>•</dt>
<dd>irregular heartbeat (<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></dd>
</dl></td>
<td class="Botrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in the hands, feet, lips, or tongue</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></dd>
<dt>•</dt>
<dd>abnormal behavior</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span></dd>
<dt>•</dt>
<dd>unsteady movement</dd>
<dt>•</dt>
<dd>inability to concentrate</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
</dl></td>
</tr></tbody>
</table>
<p>If not treated early, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may worsen and the person may have severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Signs of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> include:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl>
<p><span class="Bold">Pregnancy</span>. GlucaGen<span class="Sup">®</span> is for use only during sudden, severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic attacks</span>. </p>
<p><span class="Bold">Nursing Mothers.</span> It is not known if GlucaGen<span class="Sup">®</span> passes into your breast milk. GlucaGen<span class="Sup">®</span> does not stay in your body very long. <span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins and herbal supplements. </p>
<p>GlucaGen<span class="Sup">® </span>may affect the way other medicines work, and other medicines may affect how GlucaGen<span class="Sup">® </span>works. </p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. </p>
<p><span class="Bold">What are the possible side effects of GlucaGen<span class="Sup">®</span>?</span></p>
<p><span class="Bold">GlucaGen</span><span class="Sup">®</span><span class="Bold"> may cause serious side effects including:</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. Symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>•</dt>
<dd>raised red patches on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue or throat</dd>
<dt>•</dt>
<dd>problems breathing or swallowing</dd>
<dt>•</dt>
<dd>very high or very <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></dd>
<dt>•</dt>
<dd>fast or slow heartbeat</dd>
</dl>
</dd>
</dl>
<p>The most common side effects of GlucaGen<span class="Sup">® </span>include:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
</dl>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of GlucaGen<span class="Sup">®</span>. For more information ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store GlucaGen</span><span class="Sup">®</span><span class="Bold"> HypoKit<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Before mixing:</span></p>
<dl>
<dt>•</dt>
<dd>Store GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">® </span>for up to 24 months at 68°F to 77°F (20°C to 25°C).</dd>
<dt>•</dt>
<dd>Do not freeze GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span>. </dd>
<dt>•</dt>
<dd>Keep GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">® </span>in the original package to protect from light. </dd>
<dt>•</dt>
<dd>Do not use GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">® </span>after the expiration date printed on the package. </dd>
</dl>
<p><span class="Bold">After mixing:</span></p>
<dl>
<dt>•</dt>
<dd>Mixed GlucaGen<span class="Sup">® </span>should be used right away. </dd>
<dt>•</dt>
<dd>GlucaGen<span class="Sup">®</span> and the syringe with sterile water that comes in the kit, do not contain preservatives and should only be used one time. Throw away any unused medicine.</dd>
</dl>
<p>Keep GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span>, all medicines, needles and syringes out of the reach of children.</p>
<p><span class="Bold">What are the ingredients in the GlucaGen</span><span class="Sup">®</span><span class="Bold"> HypoKit<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Active Ingredient: </span>glucagon [rDNA origin] for injection</p>
<p><span class="Bold">Inactive ingredients: </span>lactose, sterile water for reconstitution</p>
<p>Date of Issue: April 25, 2014<br>Version: 3</p>
<p>GlucaGen<span class="Sup">®</span> and HypoKit<span class="Sup">®</span> are registered trademarks of Novo Nordisk A/S</p>
<p>© 1998-2014 Novo Nordisk</p>
<p>For information contact:<br>Novo Nordisk Inc.<br>800 Scudders Mill Road<br>Plainsboro, NJ 08536<br>1-800-727-6500<br>www.novonordisk-us.com</p>
<p>Manufactured by:<br>Novo Nordisk A/S<br>2880 Bagsvaerd, Denmark </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_fc88aee8-6d9a-413e-9b53-48fd2b3cfa50"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">novo nordisk<span class="Sup">®</span></p>
<p><span class="Bold">NDC 0169-7065-15</span></p>
<p><span class="Bold">GlucaGen</span><span class="Sup">® </span><span class="Bold">HypoKit</span></p>
<p>(glucagon [rDNA origin] for injection)</p>
<p>Emergency Use for Low Blood Sugar</p>
<p>1 mg per vial</p>
<p>Single use only. Discard unused portion.</p>
<p><span class="Bold">Protect from light</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">This kit contains: </span></p>
<p><span class="Bold">1 vial GlucaGen</span><span class="Sup">® </span><span class="Bold">for injection 1mg,</span></p>
<p><span class="Bold">1 prefilled syringe of Sterile Water for </span></p>
<p><span class="Bold">Reconstitution – for use as diluent</span></p>
<p>After reconstitution, the resulting GlucaGen<span class="Sup">®</span></p>
<p>solution contains 1mg/mL of Glucagon.</p>
<p><span class="Bold">IMPORTANT - Read the enclosed insert</span></p>
<p><span class="Bold">carefully for directions before using.</span></p>
<p><span class="Bold">Usual Dose</span> - 1 mg per vial for subcutaneous,</p>
<p>intramuscular or intravenous injection in</p>
<p>adults and pediatric patients (55 lbs or greater).</p>
<p>Smaller pediatric patients see enclosed insert.</p>
<p>Mix immediately before use. </p>
<p>Add the entire content of the accompanying </p>
<p>syringe of Sterile Water for Reconstitution </p>
<p>into the GlucaGen<span class="Sup">®</span> vial. </p>
<p>Mix well and gently withdraw the entire </p>
<p>contents of the vial back into the syringe. </p>
<p>NON-RETURNABLE</p>
<p><span class="Bold">Before Mixing: Store at controlled room</span></p>
<p><span class="Bold">temperature 20° to 25° C (68° to 77° F)</span></p>
<p><span class="Bold">Novo Nordisk Inc.</span></p>
<p>Plainsboro, NJ 08536</p>
<p>www.novonordisk-us.com</p>
<p>1-800-727-6500</p>
<p>Manufactured by:</p>
<p><span class="Bold">Novo Nordisk A/S</span></p>
<p>2880 Bagsvaerd, Denmark</p>
<p>8-9402-31-201-4</p>
<p>Exp/Lot:</p>
<div class="Figure">
<a name="id1357"></a><img alt="GlucaGen Hypokit Carton- 1 pack " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-14.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_eb41ce0c-d767-411a-ba4b-fa1d6a4cee46"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">novo nordisk<span class="Sup">®</span></p>
<p><span class="Bold">GlucaGen</span><span class="Sup">® </span><span class="Bold">HypoKit</span><span class="Sup">®</span></p>
<p><span class="Bold">NDC 0169-7065-21</span></p>
<p><span class="Bold">(Contains 2 of NDC 0169-7065-15)</span></p>
<p><span class="Bold">LIST 706521</span></p>
<p>(glucagon [rDNA origin] for injection)</p>
<p>Emergency Use for Low Blood Sugar</p>
<p>1 mg per vial</p>
<p><span class="Bold">Single use only. Discard unused portion</span></p>
<p><span class="Bold">Protect from light</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">This carton contains 2 packs of GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span>.</span></p>
<p><span class="Bold">Each kit contains: 1 vial GlucaGen<span class="Sup">®</span> for injection 1 mg, </span></p>
<p><span class="Bold">1 prefilled syringe of Sterile Water for Reconstitution – for use as diluent</span></p>
<p>After reconstitution, the resulting GlucaGen<span class="Sup">® </span>solution contains 1 mg/mL of Glucagon.</p>
<p><span class="Bold">IMPORTANT – Read the enclosed insert carefully for directions before using.</span></p>
<p><span class="Bold"><span class="Italics">Carton contains 2 packs of GlucaGen<span class="Sup">®</span> HypoKit<span class="Sup">®</span></span></span></p>
<div class="Figure">
<a name="id913814903"></a><img alt="GlucaGen Hypokit Carton- 2 pack " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f09feb8e-6651-4708-a811-bb5264712059&amp;name=83b3a882-0d44-4e4b-bb1c-3756b39449c1-15.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GLUCAGEN HYPOKIT 		
					</strong><br><span class="contentTableReg">glucagon hydrochloride kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0169-7065</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0169-7065-15</td>
<td class="formItem">1  in 1 KIT; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0169-7065-21</td>
<td class="formItem">2  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0169-7065-15</td>
<td class="formItem">1  in 1 KIT; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 SYRINGE, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>GLUCAGEN 		
					</strong><br><span class="contentTableReg">glucagon hydrochloride injection, powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GLUCAGON HYDROCHLORIDE</strong> (GLUCAGON) </td>
<td class="formItem">GLUCAGON</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">107 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020918</td>
<td class="formItem">06/22/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">1 mL  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 SYRINGE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020918</td>
<td class="formItem">06/22/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020918</td>
<td class="formItem">06/22/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novo Nordisk
							(622920320)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novo Nordisk A/S</td>
<td class="formItem"></td>
<td class="formItem">306711800</td>
<td class="formItem">MANUFACTURE(0169-7065), API MANUFACTURE(0169-7065)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9259c4a2-73e1-463b-8b3c-3a8eb3c4bdf0</div>
<div>Set id: f09feb8e-6651-4708-a811-bb5264712059</div>
<div>Version: 8</div>
<div>Effective Time: 20141212</div>
</div>
</div> <div class="DistributorName">Novo Nordisk</div></p>
</body></html>
